• Syed I Khalid, Kyle B Thomson, Sai Chilakapati, Ravi Singh, Cody Eldridge, Ankit I Mehta, and Owoicho Adogwa.
• Department of Neurosurgery, University of Illinois at Chicago, Chicago, Illinois, USA. Electronic address: syed.khalid@me.com.
• World Neurosurg. 2022 Aug 1; 164: e119-e126.

ObjectiveWhile there are several reports on the impact of smoking tobacco on spinal fusion outcomes, there is minimal literature on the influence of modern smoking cessation therapies on such outcomes. Our study explores the outcomes of single-level lumbar fusion surgery in active smokers and in smokers undergoing recent cessation therapy.MethodsMARINER30, an all-payer claims database, was utilized to identify patients undergoing single-level lumbar fusions between 2010 and 2019. The primary outcomes were the rates of any complication, symptomatic pseudarthrosis, need for revision surgery, and all-cause readmission within 30 and 90 days.ResultsThe exact matched population analyzed in this study contained 31,935 patients undergoing single-level lumbar fusion with 10,645 (33%) in each of the following groups: (1) active smokers; (2) patients on smoking cessation therapy; and (3) those without any smoking history. Patients undergoing smoking cessation therapy have reduced odds of developing any complication following surgery (odds ratio 0.86, 95% confidence interval 0.80-0.93) when compared with actively smoking patients. Nonsmokers and patients on cessation therapy had a significantly lower rate of any complication compared with the smoking group (9.5% vs. 17% vs. 19%, respectively).ConclusionsWhen compared with active smoking, preoperative smoking cessation therapy within 90 days of surgery decreases the likelihood of all-cause postoperative complications. However, there were no between-group differences in the likelihood of pseudarthrosis, revision surgery, or readmission within 90 days.Copyright © 2022 Elsevier Inc. All rights reserved.

18 keywords...

hide…